Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Korean Journal of Medicine ; : 459-463, 2015.
Artículo en Coreano | WPRIM | ID: wpr-194217

RESUMEN

Bortezomib (Velcade(R)) came into the spotlight as a target therapy for multiple myeloma. It acts through reversible inhibition of intracellular proteasomes, which triggers apoptosis, with relative selectivity for malignant cells. It has been hypothesized that the accumulation of damaged proteins in myocytes impairs cardiac function. Cardiotoxicity is a rare side effect of bortezomib treatment. We report a case of reversible systolic heart failure that probably occurred after bortezomib treatment in a patient with multiple myeloma. Patients being treated with bortezomib who have previously had cardiac comorbidities should undergo routine cardiac monitoring.


Asunto(s)
Humanos , Apoptosis , Comorbilidad , Insuficiencia Cardíaca , Insuficiencia Cardíaca Sistólica , Mieloma Múltiple , Células Musculares , Bortezomib
2.
Korean Journal of Medicine ; : 632-636, 2014.
Artículo en Coreano | WPRIM | ID: wpr-151950

RESUMEN

Primary autoimmune myelofibrosis, the development of which is not preceded by a well-defined autoimmune disease, has recently been defined as a distinct clinicopathologic syndrome. We report herein a case of a 68-year-old woman who was diagnosed with primary autoimmune myelofibrosis and present a review of the literature. The patient manifested peripheral pancytopenia, was positive for autoantibodies, and developed myelofibrosis with no preceding autoimmune or hematologic disorders. Her condition was dramatically improved after administration of prednisolone.


Asunto(s)
Anciano , Femenino , Humanos , Autoanticuerpos , Enfermedades Autoinmunes , Pancitopenia , Prednisolona , Mielofibrosis Primaria
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA